Last Updated: January 10, 2021


Featured Articles

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

TAG’s 2019 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | July 2019

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
News Updates

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States | December 29, 2021

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

ViiV Healthcare | December 21, 2020

Update to CDC's Treatment for Gonococcal Infections, 2020

CDC | December 18, 2020

Fact Sheet for Recipients and Caregivers: Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older

FDA | December 2020

IAS Panel Releases Updated 2020 Guidelines on ART and HIV Prevention 

Infectious Disease Advisor | December 4, 2020

Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill 

NPR | November 19, 2020

Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications 

Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck | November 16, 2020

Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg

FDA | November 2, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV | October 17, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV | October 16, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment 

POZ | October 16, 2020

Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients 

BSA bureau | October 15, 2020

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel

Journal of the American Medical Association | October 14, 2020

Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In 

POZ | October 9, 2020

Dentists, do you know which drugs do not mix with remdesivir?

Dr Bicuspid | October 8, 2020

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified | October 8, 2020

HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function

POZ | October 7, 2020

Injectable HIV therapy should save money if adherence is better than to oral therapies 

aidsmap | October 7, 2020

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial 

PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1

Gilead's Truvada faces Teva generics assault amid Descovy switching campaign 

FiercePharma | October 2, 2020

ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

ViiV Healthcare | September 28, 2020

Pharmacists Play a Critical Role in Managing Changes to HIV Care During COVID-19 

Pharmacy Times | September 16, 2020

Integrase Inhibitors Tied to Fewer Potentially Harmful Drug Interactions

POZ | August 31, 2020

FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling

FDA | August 6, 2020

Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial 

Antimicrob Agents Chemother. 2020 Aug 3;AAC.00838-20. doi: 10.1128/AAC.00838-20

PREZCOBIX and EVOTAZ: Pediatric Label Updates

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet | July 25, 2020

EPCLUSA: updates to labeling (liver transplant)

Long-acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

NIH | July 7, 2020

Dolutegravir Use at Conception Not Tied to Neural Tube Defects After All

POZ | July 7, 2020

The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection

AIDS 2020: 23rd International AIDS Conference Virtual, July 6-10, 2020

HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men

IAC 2020 July 6-10 Virtual SF

New Findings on Gilead's Biktarvy Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults | July 4, 2020

Clinical targeting of HIV capsid protein with a long-acting small molecule

Nature. 2020 Jul 1. doi: 10.1038/s41586-020-2443-1

New Data Shows Promise Involving Lenacapavir for the Treatment of HIV 

BioSpace | July 2, 2020

Treatment Action Group’s 2020 HIV Pipeline Report 

TAG | July 2020

RUKOBIA: New Drug Approved for HIV-1

FDA | July 2020

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020

Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research

Expert Opin Drug Deliv. 2020 Jun 17. doi: 10.1080/17425247.2020.1783233

FDA expands Gardasil 9 approval for head and neck cancer prevention

Healio | June 15, 2020

FDA Approves Drug to Treat Infants and Children with HIV

FDA | June 12, 2020

Safety highlights from the DISCOVER Trial

Gilead | June 2020

Trivicay Now Available for Babies as Young as 4 Weeks

Infectious Disease Special Edition | June 12, 2020

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2020 Annual Report

NASTAD | June 5, 2020

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

NIH | May 22, 2020

New COVID-19 CDC Resources on PrEP and Liver Disease | May 21, 2020

NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men, and Transgender Women | May 18, 2020

HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe 

Infectious Disease Advisor | May 7, 2020

FDA authorizing the emergency use of remdesivir for treatment of COVID-19

Updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database

NASTAD | April 2020

NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate

NIH | April 2, 2020

Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection

NCBI | March 2020

ADAP Advocacy Association Applauds Pharmaceutical Industry Efforts on Protecting the Drug Supply Chain during the Coronavirus Pandemic 

ADAP Advocacy Association | March 26, 2020

ViiV Healthcare on Friday announced that Health Canada has approved Cabenuva (cabotegravir and rilpivirine)

The Pharma Letter | March 21, 2020

EPCLUSA: Labeling Updates for Pediatric Patients

FDA | March 19, 2019

Newer anti-HIV drugs safest, most effective during pregnancy

NIH | March 11, 2020


CROI 2020 March 11

New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults

Gilead Sciences, Inc | March 9, 2020

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

ViiV | March 9, 2020

Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV

CROI 2020, March 8-11, 2020, Boston

Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch

CROI 2020, March 8-11, 2020, Boston

F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks

CROI 2020, March 8-11, 2020, Boston

Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP

CROI 2020, March 8-11, 2020, Boston

Maraviroc Does Not Demonstrate Clinical Benefit in Advanced HIV 

Infectious Disease Advisor | March 5, 2020

SYMTUZA: Pediatric Labeling Updates

FDA | March 4, 2020

Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach

The New England Journal of Medicine | March 4, 2020

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead Sciences, Inc | November 8, 2019

A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have

ADAP Advocacy Association | February 27, 2020

Rockefeller grants commercial license for the development of new HIV drugs

Rockerfeller | February 26, 2020

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.

Adding maraviroc to standard treatment for advanced HIV does not improve outcomes 

Healio | February 10, 2020

Just one dose of HPV vaccine may confer durable cervical cancer protection

Healio | February 10, 2020

AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

abbvie | January 31, 2020

VEMLIDY: Labeling Updates

FDA | February 4, 2020

Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016

CDC | January 31, 2020

A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

NATAP | January 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

ViiV Healthcare | London, 10 January 2020

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020

FDA Programs to Register HIV Drugs for Use in Resource-Constrained Settings 

Infectious Disease Advisor | January 3, 2020

Following backlash, Facebook disables misleading HIV medication ads

Dec. 30, 2019, 3:44 PM EST

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study

Clinical Infectious Diseases 27 December 2019

What's New in the Guidelines?

aidsinfo | December 2019

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

ViiV Healthcare | December 21, 2019

Prescribing practices for pregnant women with HIV not aligned with guidelines 

Healio | December 18, 2019

Facebook ads are spreading lies about anti-HIV drug PrEP. The company won't act 

The Guardian | December 14, 2019

Cost prevents 7% of people will HIV from adhering to medication 

Healio | December 12, 2019

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Viiv | December 5, 2019

HARVONI, EPCLUSA, and VOSEVI Labeling updates: HCV-infected adults with severe renal impairment

FDA | November 18, 2019

CDC Antibiotic Resistance: New Threats Report

Understanding the Medicaid Prescription Drug Rebate Program – Kaiser Family Foundation

KFF | November 12, 2019

Untangling the Trump administration's lawsuit over an HIV prevention drug 

Science Magazine | November 8, 2019

Facts About Gilead’s PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts

NATAP | November 4, 2019 at 12:01:02 PM EST

Gilead Perspective on HHS Lawsuit

The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV

17th European AIDS Conference, November 6-9, 2019, Basel

Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort

17th European AIDS Conference, November 6-9, 2019, Basel

INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure

17th European AIDS Conference, November 6-9, 2019, Basel

Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys

17th European AIDS Conference, November 6-9, 2019, Basel

DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate

17th European AIDS Conference, November 6-9, 2019, Basel

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead | November 8, 2019

BARACLUDE: Updates to Adverse Reactions from Long-Term Observational Study

FDA | November 8, 2019

Label updates to efavirenz containing products

FDA | October 30, 2019

Hepatitis C Treatments Are Safe and Effective for Seniors

POZ | October 28, 2019

Dolutegravir and risk of neural tube defects: Labeling Updates

FDA | October 25, 2019

Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work

The Body Pro | October 16, 2019

Rapid ART Initiation: A New Model Presents Unique Opportunities and Challenges | October 11, 2019

The 8th World Workshop on Oral Health and Disease in AIDS

BRITISH DENTAL JOURNAL | VOLUME 227 NO. 7 | October 11 2019

Photos courtesy of Dr. David Croser

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

ViiV Healthcare | October 2, 2019

MAVYRET: new dosage regimen and labeling updates

FDA | October 1, 2019

FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options

NATAP | September 26, 2019

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

Business Wire | September 20, 2019

Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV

Yahoo Finance | September 19, 2019

FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease

FDA | August 28, 2019

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

GSK | August 22, 2019

Extensive Drug Resistance Has Become Rare Among People With HIV

POZ | August 19, 2019

FDA panel backs Gilead's HIV prevention drug for certain population

Reuters | August 7, 2019

BIKTARVY: recent changes to labeling

FDA | August 6, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational ... 

Yahoo Finance | July 29, 2019

WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For ... 

Kaiser Family Foundation | July 23, 2019

Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir

EurekAlert | July 23, 2019

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

The Lancet | July 12, 2019

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 

aidsinfo | July 10, 2019

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

BioSpace | July 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

ViiV Healthcare | July 10, 2019

GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen 

Reuters | July 10, 2019

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

BioSpace | July 9, 2019

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

ViiV Healthcare | July 8, 2019

TRUVADA: Important Updates to the REMS

FDA: HIV Email Updates | July 1, 2019

Long-Acting Antiretrovirals for Treatment 

NASTAD | June 26, 2019

HIV Updates: BIKTARVY label revisions

HIV drug cabotegravir not associated with weight gain

Healio | June 8, 2019

AIDS groups criticize Express Scripts for excluding several HIV medicines

STAT | June 6, 2019

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2019 Annual Report

NASTAD | June 6, 2019

Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Baseline genotype testing at HIV diagnosis not cost-effective

Healio | May 13, 2019

Gilead to Donate Up to 2.4M Bottles of HIV Prevention Pills Each Year in the U.S.

POZ | May 10, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

NIH | May 9, 2019

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet | May 5, 2019

ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment

WRAL Tech Wire | April 29, 2019

MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication

AIDS Behav. 2018 Apr;22(4):1158-1164. doi: 10.1007/s10461-017-1972-6

Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591

NATAP | April 10, 2019

NATAP: HIV-Drug Resistance Testing/DHHS Guidelines

Last Updated: October 25, 2018

ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection

ViiV | April 26, 2019

New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds

POZ | April 23, 2019

Special thanks to The AIDS Institute for leading the charge on this important issue

Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

NATAP | April 18, 2019

FDA Has Approved New Two-Drug Regimen to Treat People with HIV

Healthline | April 15, 2019

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

Janssen | April 11, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA | April 8, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Market Watch |  Apr 9, 2019

Pharma giant profits from HIV treatment funded by taxpayers and patented by the government

Washington Post | March 26, 2019

Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

Gilead | March 26, 2019

Long-acting injectable treatment maintains viral suppression

aidsmap | March 8, 2019

Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable

Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle

Integrase inhibitor treatment leads to greater weight gain

aidsmap | March 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

ViiV | March 7, 2019

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead | February 11, 2019

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

NIH | February 8, 2019

FDA Hepatitis Update- VEMLIDY labeling revised (renal information)

FDA | February 6, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

University of Nebraska Medical Center | December 21, 2018

Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata


FDA | December 11, 2018

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet | November 9, 2018

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov

FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label

FDA | November 7, 2018

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

NIH | November 7, 2018

NASTAD Announces the Release of

NASTAD | November 6, 2018

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

NATAP | November 6, 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...

aidsmap | November 2018

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...

aidsmap | November 2, 2018

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

aidsmap | November 1, 2018

FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates

FDA | October 31, 2018

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow